{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Previously Marketed
Source:
Aptrol by Smith Kline & French
(1949)
Source URL:
First approved in 1949
Source:
Aptrol by Smith Kline & French
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
US Previously Marketed
Source:
SODIUM BUTABARBITAL by IVAX SUB TEVA PHARMS
(1973)
Source URL:
First approved in 1939
Source:
BUTISOL SODIUM by MYLAN SPECIALITY LP
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Barbiturates are non-selective depressants of the central nervous system. Butabarbital is one of them, which is used under brand name butisol sodium as a sedative or hypnotic. Like other barbiturates, butabarbital is capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. The mechanism of action by which barbiturates exert their effect is not yet completely understood, but is assumed, that butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Status:
US Previously Marketed
Source:
Plasmoquine E
(1938)
Source URL:
First approved in 1938
Class (Stereo):
CHEMICAL (RACEMIC)
Quinacrine was initially developed as an anti-malarial drug marketed under the name Atabrine. Also it was approved for the teratment of ascites, however it was wothdrawn for both indication in 1995 and 2003, respectively. The drug is also used for the treatment of giardiasis, lupus, rheumatoid arthritis, refractory pulmonary effusion and pneumothorax, induce female sterilization etc. Proposed mechanisms of action include DNA intercalation interference with RNA transcription and translation, inhibition of succinate oxidation interference with electron transport, inhibition of cholinesterase, and inhibitor of phospholipase.
Status:
US Previously Marketed
Source:
Plasmoquine E
(1938)
Source URL:
First approved in 1938
Class (Stereo):
CHEMICAL (RACEMIC)
Quinacrine was initially developed as an anti-malarial drug marketed under the name Atabrine. Also it was approved for the teratment of ascites, however it was wothdrawn for both indication in 1995 and 2003, respectively. The drug is also used for the treatment of giardiasis, lupus, rheumatoid arthritis, refractory pulmonary effusion and pneumothorax, induce female sterilization etc. Proposed mechanisms of action include DNA intercalation interference with RNA transcription and translation, inhibition of succinate oxidation interference with electron transport, inhibition of cholinesterase, and inhibitor of phospholipase.
Status:
US Previously Marketed
Source:
Ammoniated Glycyrrhizin U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Ammoniated Glycyrrhizin U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the
potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate
is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1,
1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.
Status:
US Previously Marketed
Source:
Ammoniated Glycyrrhizin U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Ammoniated Glycyrrhizin U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the
potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate
is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1,
1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.
Status:
US Previously Marketed
Source:
Ethylmorphine Hydrochloride U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Ethylmorphine Hydrochloride U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Ethylmorphine is a derivative of morphine with analgesic and antitussive effect. It acts by activating the opioid receptors and thus has a direct influence on the CNS system. Ethylmorphine was approved in Europe for the treatment of dry cough (Codethyline, Dionine).
Status:
US Previously Marketed
Source:
Ammoniated Glycyrrhizin U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Ammoniated Glycyrrhizin U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the
potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate
is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1,
1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.
Status:
US Previously Marketed
Source:
Ammoniated Glycyrrhizin U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Ammoniated Glycyrrhizin U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the
potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate
is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1,
1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.
Status:
US Previously Marketed
Source:
Aconitine U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Aconitine is an alkaloid found in the Aconitum species. Aconitine is a highly toxic cardiotoxin and neurotoxin. In China and other countries, the herbal extract containing aconitine was used for the treatment of pain in musculoskeletal disorders, however the safety margin between therapeutic analgesic effect of aconitine and its known cardiotoxic effect is so narrow that the treatment may cause poisoning and death. The mechanism of aconitine action is explained by its ability to activate voltage-dependent sodium-ion channels.